Amgen launches $5B buyback
Amgen said Nov. 7 that it plans to buy back $5 billion of its shares as part of a push to return profit to stockholders. Shares of the Thousand Oaks-based drugmaker jumped 4.5 percent in morning trading. Moody’s Investors Service and Fitch Ratings lowered their ratings on Amgen debt after the announcement because the biotech Read More →
Read More →Hold that thought: Thousand Oaks entrepreneur Turpel pens book
Pete Turpel opens “Holding Power,” his recently released book, with a story about how he did something all of us think about doing — sometimes more than once a day. He threw away his smart phone. In fairness to smart phones, it was a BlackBerry, a less cool and perhaps more intrusive device than the Read More →
Read More →
Special brew: Indy coffee shops hold their own against big boys
Independent coffee shops in the Tri-Counties are thriving, despite competition with Starbucks and other big names.
Read More →Group lends business voice to city hall
“You can’t fight city hall.” So goes the old saying. But in Thousand Oaks, business owners are part of city hall through a group called the Business Roundtable.
Read More →High-tech mapping: VSolveit garners USDA awards
Mapping company VSolvit recently garnered national USDA awards.
Read More →Amgen drug shows blockbuster promise
Putting test results behind the talk at its recent product pipeline review, Thousand Oaks-based Amgen on May 17 released promising results for the Xgeva variant of its potential blockbuster bone drug denosumab.
Read More →
Sponsored content:
2015-2016 Giving Guide
